Hepatoma Research

Scope & Guideline

Transforming Knowledge into Clinical Practice

Introduction

Welcome to the Hepatoma Research information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Hepatoma Research, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2394-5079
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationHEPATOMA RES / Hepatoma Res.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

Hepatoma Research is dedicated to advancing the understanding and treatment of liver cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. The journal emphasizes innovative research methodologies that span clinical, translational, and basic science, aiming to improve patient outcomes and treatment modalities.
  1. Hepatocellular Carcinoma (HCC) Research:
    The journal focuses extensively on various aspects of HCC, including its risk factors, molecular mechanisms, treatment strategies, and outcomes, thereby contributing to a better understanding of this prevalent liver cancer.
  2. Cholangiocarcinoma Studies:
    Cholangiocarcinoma, another critical area of focus, is explored through studies that cover its epidemiology, molecular pathology, and treatment advancements, highlighting the need for improved management strategies.
  3. Innovative Treatment Modalities:
    There is a consistent emphasis on novel treatment approaches, including minimally invasive surgeries, radiation therapies, and the use of immunotherapy and targeted therapies, reflecting the journal's commitment to advancing clinical practice.
  4. Multidisciplinary Approaches:
    The journal promotes multidisciplinary research and treatment approaches, integrating perspectives from surgery, oncology, radiology, and pathology to provide comprehensive care for liver cancer patients.
  5. Patient-Centric Research:
    Hepatoma Research also prioritizes research that addresses patient perspectives, quality of life, and real-world outcomes, fostering a holistic understanding of treatment impacts.
The journal has shown a dynamic evolution in its research focus, with several emerging themes gaining significant attention in recent publications. These trends reflect the ongoing advancements in understanding liver cancer and the pursuit of innovative treatment strategies.
  1. Immunotherapy and Checkpoint Inhibitors:
    Recent publications highlight the growing interest in immunotherapy, particularly immune checkpoint inhibitors, as promising treatment options for HCC, reflecting a shift towards harnessing the immune system in cancer treatment.
  2. Minimally Invasive Surgical Techniques:
    There is an increasing trend in research dedicated to minimally invasive surgical techniques for liver cancer treatment, indicating a broader acceptance and application of these approaches in clinical practice.
  3. Molecular and Genetic Profiling:
    Emerging studies focus on the molecular and genetic profiling of liver cancers, which is crucial for the development of personalized medicine strategies and targeted therapies.
  4. Microbiome and Liver Health:
    Recent articles explore the relationship between the gut microbiome and liver diseases, signaling an emerging interest in how microbial health impacts liver cancer development and progression.
  5. Real-World Data and Patient Outcomes:
    An emphasis on real-world data analysis and patient outcomes has emerged, reflecting a growing interest in understanding the effectiveness and impact of treatments in diverse populations.

Declining or Waning

As the field of liver cancer research evolves, certain themes appear to be diminishing in prominence within the journal's recent publications. These waning scopes may reflect shifts in research priorities or advancements in understanding that render previous approaches less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in papers focusing on conventional chemotherapy regimens for liver cancer, as newer targeted therapies and immunotherapies gain traction and demonstrate better efficacy.
  2. Basic Science without Clinical Application:
    Research that solely delves into basic science without a clear translational application seems to be less prominent, indicating a shift towards studies that emphasize clinical relevance and applicability in patient care.
  3. Liver Cancer Surveillance Protocols:
    While surveillance remains crucial, the frequency of studies focused on traditional surveillance protocols has decreased, possibly due to increased emphasis on personalized and risk-based screening strategies.

Similar Journals

Clinical and Molecular Hepatology

Elevating understanding and treatment of liver conditions.
Publisher: KOREAN ASSOC STUDY LIVERISSN: 2287-2728Frequency: 4 issues/year

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Oncologie

Transforming cancer treatment through rigorous research.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

International Journal of Clinical Oncology

Advancing the Frontiers of Cancer Care
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

World Journal of Gastrointestinal Oncology

Exploring groundbreaking studies in gastrointestinal oncology.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Thoracic Cancer

Fostering collaboration for lung cancer solutions.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Hepatobiliary & Pancreatic Diseases International

Championing excellence in hepatobiliary and pancreatic research.
Publisher: ELSEVIERISSN: 1499-3872Frequency: 6 issues/year

Hepatobiliary & Pancreatic Diseases International, an esteemed journal published by Elsevier, stands as a vital resource within the field of gastroenterology and hepatology. Established in 2002, this journal has developed a significant reputation, currently ranked in the second quartile (Q2) in both categories as of 2023, showcasing its commitment to high-quality research and clinical studies. Based in Singapore, Hepatobiliary & Pancreatic Diseases International serves as an essential platform for researchers, clinicians, and healthcare professionals to share innovative findings, therapeutic approaches, and advancements in the understanding of hepatobiliary and pancreatic diseases. Although the journal does not currently offer Open Access, its rigorous peer-review process ensures that published articles maintain the highest scientific standards, fostering knowledge dissemination among the global research community. With a convergence period extending to 2024, this journal continues to play a pivotal role in enhancing the understanding and treatment of complex gastrointestinal conditions, making it a must-read for anyone engaged in this dynamic field.

Liver Cancer

Connecting researchers to the forefront of liver cancer studies.
Publisher: KARGERISSN: 2235-1795Frequency: 6 issues/year

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Clinical and Experimental Hepatology

Transforming Findings into Clinical Excellence
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 2392-1099Frequency: 4 issues/year

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

Cancer Reports

Elevating cancer knowledge to improve patient outcomes.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Clinical Lung Cancer

Advancing lung cancer research for a healthier tomorrow.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.